8-K current report · filed Nov 5, 2026

Intellia Therapeutics, Inc. (NTLA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1NTLA overview

Short answer

Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and business updates announced for quarter ended September 30, 2026.

Intellia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results and business updates announced for quarter ended September 30, 2026
  • Full results and operating developments available in Exhibit 99.1, the investor-relevant source for detailed figures and outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 results support a potential 2027 commercial inflection, with lonvo-z BLA priority review and March 10, 2027 PDUFA date
  • Commercial launch preparation underway, including field organization deployment and payer engagement for a planned first-quarter 2027 launch
  • Cash and marketable securities $614.8M, expected to fund operations into 2028, excluding lonvo-z revenue and up to $400M OrbiMed term loan
  • MAGNITUDE-2 Phase 3 enrollment completed above 60-patient target, while ATTR-CM enrollment advanced
  • Net loss widened to $127.5M from $101.3M, as G&A rose to $46.1M for commercial infrastructure investment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Intellia Therapeutics, Inc. 8-K filings

Get the next NTLA 8-K as it lands

Follow NTLA for push alerts, or ask the research agent what this filing means.